Duvakitug, a treatment for colitis and Crohn’s disease, surpassed expectations and positions Teva to compete in the $28 billion global inflammatory bowel disease market | Read More ynet – Business | Read More in Virtual Jerusalem. Read More in Israel NOWlej.